Developer docs
API playgroundTry for free, no card

Search company profiles

Voluntis

Full company profile

uuid0005olv

Namestring
Voluntis
Legal namestring
Voluntis
Websiteurl
voluntis.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Voluntis is a France-based, public digital health company (EPA: ALVTX) founded in 2001 and now operating as Aptar Digital Health, a division of Aptar Pharma. The company builds a certified, cloud-native digital health platform that delivers companion apps, connected drug-delivery devices, Software as a Medical Device (SaMD), digital Patient Support Programs, and Study & Data Services to global pharmaceutical and biotech partners across 120 countries. Its portfolio includes proprietary consumer-facing apps (Migraine Buddy, Esme for multiple sclerosis, Allergy Buddy), connected drug-delivery hardware such as the FDA 510(k)-cleared HeroTracker Sense, and AI-powered screening algorithms licensed to AstraZeneca.

The platform is underpinned by ISO 13485, ISO 27001, MDSAP, HIPAA, and GDPR certifications and is designed for integration with EHRs, sensors, hubs, and patient support workflows. Voluntis monetizes through multi-year enterprise SaaS subscriptions with pharma and biotech partners, connected device sales, IP licensing (e.g., AstraZeneca AI screening algorithms), and professional services for virtual clinical studies and real-world evidence generation. Its named enterprise customers include AbbVie, Bristol Myers Squibb, Chiesi, Eisai, Novartis, Sanofi, AstraZeneca, and Stallergenes Greer, with partnerships extending to medical device manufacturers (Enable Injections), consumer health products (Oura), and healthcare providers (Moffitt Cancer Center).

The business model is enterprise B2B sales-led, with co-developed and tailored solutions per pharma partner, supported by channel partnerships and event-driven demand generation at conferences such as CMSC and HLTH Europe. With 51–100 employees and operations spanning 120 countries, 17 clinical studies supported, and 15+ regulatory approvals, Voluntis operates as a focused mid-sized regulated digital health unit leveraging Aptar Pharma's global drug-delivery infrastructure.

Short descriptiontext

Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCongers, United States
HQ citystring
Congers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital health software, companion medical apps, connected drug delivery, patient support platforms, real world evidence
Industry4 codes
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Software Publishers51321
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Health Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1B2B Enterprise SaaS for Pharma
TypeSubscription Recurring
Description

Subscription/contract-based revenue from pharmaceutical and biotech partners licensing the digital health platform, companion apps, connected devices, and SaMD solutions. Long-term enterprise contracts with global life sciences partners.

aptardigitalhealth.com
2Connected Drug-Delivery Device Sales
TypeHardware Sales
Description

Revenue from connected drug-delivery device solutions (e.g., HeroTracker Sense) integrated with patient companion apps to capture usage and adherence data.

aptardigitalhealth.com
3Licensing Agreements
TypeLicensing Royalties
Description

Licensing revenue from agreements such as the AstraZeneca deal to develop AI-Powered Screening Algorithms, monetizing proprietary technology through IP licensing.

aptardigitalhealth.com
4Study & Data / Real-World Evidence Services
TypeProfessional Services
Description

Professional services revenue from running virtual clinical studies, post-marketing studies, and generating real-world evidence for pharma brand teams using digital capabilities.

aptardigitalhealth.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Tailored enterprise offers based on digital health project requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed; personalized offers generated through a 5-question recommendation quiz covering drug status, regulatory status, geography, and indication.

aptardigitalhealth.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Operates across 120 countries globally
+3 more records
Product overview1 text field

Aptar Digital Health — the division of Aptar Pharma that houses Voluntis — operates as a platform-plus-modules architecture delivered to global pharma and biotech partners across 120 countries. The certified, cloud-native platform underpins a portfolio of regulated companion apps (including Migraine Buddy®, Esme, and Allergy Buddy), connected drug-delivery devices (such as the FDA 510(k)-cleared HeroTracker® Sense), Software as a Medical Device (SaMD) modules, Digital PSPs, a Disease Management Platform, and Study & Data Services. The named apps (Migraine Buddy, Esme, Allergy Buddy) and HeroTracker® Sense are concrete user- or patient-facing offerings built on top of the core platform, while SaMD, Digital PSP, Disease Management Platform, and Study Support are configurable modules/engagement models used to tailor solutions to specific drugs, indications, and patient journeys.

Product and service1 record
1HeroTracker Sense
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Partnership to develop the enFuse® Companion Digital Solution, combining Enable Injections' enFuse wearable drug-delivery platform with Aptar Digital Health's digital health expertise to enhance patient experience during self-administration. Announced April 9, 2026.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Collaboration to advance migraine insights by connecting Migraine Buddy® with the Oura Ring, enabling users to correlate physiological data with migraine symptoms, triggers, and treatments. Announced January 7, 2026.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-22
Description

Licensing agreement to develop AI-Powered Screening Algorithms, leveraging Aptar Digital Health's AI capabilities under license for AstraZeneca's therapeutic areas. Announced May 22, 2025.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Operates as "A Division of Aptar Pharma", benefiting from parent company's drug delivery expertise, global pharma relationships, and operational scale.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed among "trusted partner of leading pharmaceutical companies at a global level".

6Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.

aptardigitalhealth.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.

8Eisai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.

aptardigitalhealth.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed as a trusted partner of leading pharmaceutical companies at a global level.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partner in respiratory/allergy therapeutic area leveraging the digital health platform.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Healthcare/cancer center partner supporting oncology-related digital health initiatives; logo featured on the website partner wall.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BrightInsight operates a regulated digital health platform purpose-built for pharma and biopharma, offering SaMD, companion apps, and connected device solutions. It is the closest direct peer to Voluntis in terms of regulated platform positioning and pharma/biotech GTM motion.

TypeDirect peer
Description

S3 Connected Health provides regulated digital health platforms and connected drug-delivery companion apps for global pharma. It directly competes with Voluntis in the pharma digital companion and connected-device integration space.

3Biofourmis
TypeDirect peer
Description

Biofourmis builds digital therapeutics and AI-enabled remote monitoring platforms that integrate with pharma drug programs. It is a direct peer in the regulated SaMD and pharma partnership category.

TypeDirect peer
Description

Click Therapeutics develops prescription digital therapeutics in partnership with major pharma sponsors (e.g., Otsuka). It is a direct peer in the prescription DTx and pharma co-development model.

TypeDirect peer
Description

Propeller Health (now part of ResMed) offers connected inhaler sensors and companion apps for respiratory therapy, mirroring Voluntis's HeroTracker Sense and respiratory therapeutic area focus.

TypeDirect peer
Description

mySugr (acquired by Roche) provides a chronic disease companion app ecosystem integrated with pharma and device partners. It is comparable in patient-facing companion app model and pharma partnership monetization.

TypeDirect peer
Description

Medisafe offers a medication adherence companion platform with pharma integrations. It directly competes with Voluntis in the medication adherence and patient engagement category.

TypeDirect peer
Description

WellDoc develops FDA-cleared digital therapeutics, notably for diabetes, in partnership with pharma and payers. It is a direct peer in the regulated SaMD/DTx and pharma partnership model.

9AdhereTech
TypeDirect peer
Description

AdhereTech builds connected medication adherence devices and supporting software for pharma. It is a direct peer in connected drug-delivery devices with pharma partnerships.

TypeDirect peer
Description

Huma (formerly Huma Therapeutics) operates a regulated digital health platform for hospitals, pharma, and research, including companion apps and SaMD modules. It is comparable as a regulated digital health platform with pharma partners.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Voluntis

Digital Health Softwarevoluntis.com

Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.

What Voluntis does

Voluntis is a France-based, public digital health company (EPA: ALVTX) founded in 2001 and now operating as Aptar Digital Health, a division of Aptar Pharma. The company builds a certified, cloud-native digital health platform that delivers companion apps, connected drug-delivery devices, Software as a Medical Device (SaMD), digital Patient Support Programs, and Study & Data Services to global pharmaceutical and biotech partners across 120 countries. Its portfolio includes proprietary consumer-facing apps (Migraine Buddy, Esme for multiple sclerosis, Allergy Buddy), connected drug-delivery hardware such as the FDA 510(k)-cleared HeroTracker Sense, and AI-powered screening algorithms licensed to AstraZeneca.

The platform is underpinned by ISO 13485, ISO 27001, MDSAP, HIPAA, and GDPR certifications and is designed for integration with EHRs, sensors, hubs, and patient support workflows. Voluntis monetizes through multi-year enterprise SaaS subscriptions with pharma and biotech partners, connected device sales, IP licensing (e.g., AstraZeneca AI screening algorithms), and professional services for virtual clinical studies and real-world evidence generation. Its named enterprise customers include AbbVie, Bristol Myers Squibb, Chiesi, Eisai, Novartis, Sanofi, AstraZeneca, and Stallergenes Greer, with partnerships extending to medical device manufacturers (Enable Injections), consumer health products (Oura), and healthcare providers (Moffitt Cancer Center).

The business model is enterprise B2B sales-led, with co-developed and tailored solutions per pharma partner, supported by channel partnerships and event-driven demand generation at conferences such as CMSC and HLTH Europe. With 51–100 employees and operations spanning 120 countries, 17 clinical studies supported, and 15+ regulatory approvals, Voluntis operates as a focused mid-sized regulated digital health unit leveraging Aptar Pharma's global drug-delivery infrastructure.

Voluntis firmographics

Firmographics
Name
Voluntis
Legal name
Voluntis
Website
https://voluntis.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.
Ownership category
akta.pro rank

Voluntis industry classification

Industry
Product category
Digital Health Software
NAICS
Software Publishers (51321)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital health software
  • Companion medical apps
  • Connected drug delivery
  • Patient support platforms
  • Real world evidence

Where Voluntis is headquartered

Location

Headquarters

HQ city
Congers
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Voluntis business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. B2B Enterprise SaaS for Pharma: Subscription/contract-based revenue from pharmaceutical and biotech partners licensing the digital health platform, companion apps, connected devices, and SaMD solutions. Long-term enterprise contracts with global life sciences partners.
  2. Connected Drug-Delivery Device Sales: Revenue from connected drug-delivery device solutions (e.g., HeroTracker Sense) integrated with patient companion apps to capture usage and adherence data.
  3. Licensing Agreements: Licensing revenue from agreements such as the AstraZeneca deal to develop AI-Powered Screening Algorithms, monetizing proprietary technology through IP licensing.
  4. Study & Data / Real-World Evidence Services: Professional services revenue from running virtual clinical studies, post-marketing studies, and generating real-world evidence for pharma brand teams using digital capabilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTailored enterprise offers based on digital health project requirements

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Voluntis product offering

Product offering

Core offering

Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.

Product overview

Aptar Digital Health — the division of Aptar Pharma that houses Voluntis — operates as a platform-plus-modules architecture delivered to global pharma and biotech partners across 120 countries. The certified, cloud-native platform underpins a portfolio of regulated companion apps (including Migraine Buddy®, Esme, and Allergy Buddy), connected drug-delivery devices (such as the FDA 510(k)-cleared HeroTracker® Sense), Software as a Medical Device (SaMD) modules, Digital PSPs, a Disease Management Platform, and Study & Data Services. The named apps (Migraine Buddy, Esme, Allergy Buddy) and HeroTracker® Sense are concrete user- or patient-facing offerings built on top of the core platform, while SaMD, Digital PSP, Disease Management Platform, and Study Support are configurable modules/engagement models used to tailor solutions to specific drugs, indications, and patient journeys.

Differentiator

Problem solved

Functional benefit

Products and services

  • HeroTracker Sense

Quantifiable outcome

  • Operates across 120 countries globally
  • +3 more outcomes

Companies that use Voluntis

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Voluntis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature8 records

Voluntis partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and flagship.

  • Enable InjectionscoreStrategic or Co-development Partner · 9 April 2026Partnership to develop the enFuse® Companion Digital Solution, combining Enable Injections' enFuse wearable drug-delivery platform with Aptar Digital Health's digital health expertise to enhance patient experience during self-administration. Announced April 9, 2026.
  • ŌURAcoreTechnology or Integration · 7 January 2026Collaboration to advance migraine insights by connecting Migraine Buddy® with the Oura Ring, enabling users to correlate physiological data with migraine symptoms, triggers, and treatments. Announced January 7, 2026.
  • AstraZenecaflagshipOEM/ Whitelabel/ Licensing Partner · 22 May 2025Licensing agreement to develop AI-Powered Screening Algorithms, leveraging Aptar Digital Health's AI capabilities under license for AstraZeneca's therapeutic areas. Announced May 22, 2025.
  • Aptar PharmaflagshipStrategic or Co-development PartnerOperates as "A Division of Aptar Pharma", benefiting from parent company's drug delivery expertise, global pharma relationships, and operational scale.
  • AbbViecoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed among "trusted partner of leading pharmaceutical companies at a global level".
  • Bristol Myers SquibbcoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
  • ChiesicoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
  • EisaicoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
  • NovartisflagshipStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner of leading pharmaceutical companies at a global level.
  • SanofiflagshipStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
  • Stallergenes GreercoreStrategic or Co-development PartnerPharmaceutical partner in respiratory/allergy therapeutic area leveraging the digital health platform.
  • Moffitt Cancer CentercoreImplementation/ SI/ Consulting PartnerHealthcare/cancer center partner supporting oncology-related digital health initiatives; logo featured on the website partner wall.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Voluntis competitors and assessment

Company assessment

Direct peers

  • BrightInsight: BrightInsight operates a regulated digital health platform purpose-built for pharma and biopharma, offering SaMD, companion apps, and connected device solutions. It is the closest direct peer to Voluntis in terms of regulated platform positioning and pharma/biotech GTM motion.
  • S3 Connected Health: S3 Connected Health provides regulated digital health platforms and connected drug-delivery companion apps for global pharma. It directly competes with Voluntis in the pharma digital companion and connected-device integration space.
  • Biofourmis: Biofourmis builds digital therapeutics and AI-enabled remote monitoring platforms that integrate with pharma drug programs. It is a direct peer in the regulated SaMD and pharma partnership category.
  • Click Therapeutics: Click Therapeutics develops prescription digital therapeutics in partnership with major pharma sponsors (e.g., Otsuka). It is a direct peer in the prescription DTx and pharma co-development model.
  • Propeller Health: Propeller Health (now part of ResMed) offers connected inhaler sensors and companion apps for respiratory therapy, mirroring Voluntis's HeroTracker Sense and respiratory therapeutic area focus.
  • mySugr: mySugr (acquired by Roche) provides a chronic disease companion app ecosystem integrated with pharma and device partners. It is comparable in patient-facing companion app model and pharma partnership monetization.
  • Medisafe: Medisafe offers a medication adherence companion platform with pharma integrations. It directly competes with Voluntis in the medication adherence and patient engagement category.
  • WellDoc: WellDoc develops FDA-cleared digital therapeutics, notably for diabetes, in partnership with pharma and payers. It is a direct peer in the regulated SaMD/DTx and pharma partnership model.
  • AdhereTech: AdhereTech builds connected medication adherence devices and supporting software for pharma. It is a direct peer in connected drug-delivery devices with pharma partnerships.
  • Huma: Huma (formerly Huma Therapeutics) operates a regulated digital health platform for hospitals, pharma, and research, including companion apps and SaMD modules. It is comparable as a regulated digital health platform with pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Voluntis social profiles

Digital presence

Voluntis compliance and trust

Trust signal

Compliance5 records

Voluntis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Voluntis leadership team

Management profile

Number of profiles

Profiles11 records

Voluntis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Voluntis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voluntis

What does Voluntis do?

Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.

Is Voluntis a public or private company?

Voluntis is a private company. It is classified as corporate owned and is currently operating.

When was Voluntis founded?

Voluntis was founded in 2001. It employs 101 to 250 people.

Where is Voluntis based?

Voluntis is headquartered in Congers, United States, in the North America region.

How does Voluntis make money?

Four revenue lines are on record. B2B Enterprise SaaS for Pharma is the primary driver. The others are connected Drug-Delivery Device Sales, licensing Agreements and study & Data / Real-World Evidence Services.

Who are Voluntis's main competitors?

Direct peers on record are BrightInsight, S3 Connected Health, Biofourmis, Click Therapeutics, Propeller Health, mySugr, Medisafe, WellDoc, AdhereTech and Huma.

Does Voluntis have an API?

No public API is recorded for Voluntis.

What industry is Voluntis in?

Voluntis's product category is Digital Health Software. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACAPAH, Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers). Its NAICS code is 51321 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market Research FutureAerosol Market Size, Share, Analysis & Industry Report 2035The global aerosol market is projected to grow from 100.87 billion USD in 2025 to 119.98 billion USD by 2035, driven by demand for eco-friendly products and technological innovations in delivery systems. Key industry developments include AptarGroup's acquisition of Voluntis’s aerosol division and strategic partnerships between companies like Ball Corporation and Unilever for sustainable packaging.PRLogDigital Therapeutics Market Booming Worldwide with Key Players | Pear Therapeutics, VoluntisThe global digital therapeutics market is projected to be valued at $2.2 billion in 2020 and grow rapidly. Growth is expected to be driven by expanding pharma-digital alliances, focus on mental health, improving reimbursement, and a strong product pipeline. Digital therapeutics are software programs delivering evidence-based interventions for conditions like diabetes and cardiovascular disease.BioSpaceAptar Announces the Completion of the Acquisition of a Majority Stake in VoluntisAptar completed its acquisition of a majority stake in Voluntis, paying €8.70 per share for approximately 64.6% of the company. It will launch a mandatory cash tender offer to buy the remaining shares at the same price, subject to regulatory clearance. If conditions are met, Aptar plans a squeeze-out of the remaining shares.PR NewswireDigital Therapeutics Market Size worth $13.51 Billion By 2028 | CAGR: 26.1%: Polaris Market ResearchPolaris Market Research released a report projecting the global digital therapeutics market to reach $13.51 billion by 2028, growing at a CAGR of 26.1% from 2021 to 2028, driven by increasing internet and smartphone adoption for healthcare applications. Among notable corporate developments, Pear Therapeutics announced plans to go public through a $1.6 billion SPAC merger with Thimble Point Acquisition Corp., while AptarGroup entered exclusive negotiations to acquire Voluntis. The COVID-19 pandemic accelerated digital therapeutics adoption as healthcare authorities promoted social distancing and remote patient monitoring.BioWorldAptar to expand digital therapeutics assets with Voluntis buyAptargroup Inc. is negotiating to acquire Voluntis SA, a digital therapeutics company. The deal would complement Aptar's existing digital solutions portfolio and expand services to address multiple conditions and chronic diseases. Voluntis CEO Pierre Leurent said the acquisition would enable a complete digital health platform combining connected devices and digital therapeutics.Daily HeraldAptar enters exclusive negotiations to buy VoluntisAptarGroup entered exclusive negotiations to acquire all outstanding shares of Voluntis, a digital therapeutics company. The deal would give Aptar about 64.6% ownership and add digital therapeutic solutions to its digital health portfolio. Voluntis would continue operating from its Paris and Boston offices.AptarAptar negotiates for Voluntis, a leader in digital therapeuticsAptar entered exclusive negotiations to acquire Voluntis, a digital therapeutics company, for approximately €50.8 million ($61.5 million). The deal would give Aptar access to Voluntis's Theraxium platform, which has 14 regulatory clearances, and is expected to close by the end of 2021.PR NewswireDigital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 Based on Type of Solution, Type of Therapy and Purpose of SolutionReportlinker released a comprehensive market research report on the digital therapeutics industry, covering the period 2020-2030, analyzing over 230 digital therapeutic solutions across various therapeutic areas including diabetes, mental health disorders, and chronic conditions. The report includes market forecasts, competitive analysis, investment trends, partnership activity, and features interviews with executives from seven digital health companies including Vida Health, Canary Health, Floreo, Somatix, Tilak Healthcare, Wellthy Therapeutics, and Voluntis. The report examines the impact of COVID-19 on accelerating digital health adoption and provides geographic breakdowns spanning North America, Europe, and Asia-Pacific.PR NewswireGlobal Home Infusion Therapy Market to Surpass $49.5 Billion despite the Rise of COVID-19 Crisis - Exclusive Report [165 pages] by Research DiveResearch Dive published a market research report finding that the global home infusion therapy market, valued at $20.2 billion in 2019, is now estimated to reach $49.5 billion by 2027, growing at a CAGR of 11.7% during the COVID-19 crisis period. The current market size has expanded to $22.9 billion due to increased adoption of home-based treatment by chronic disease patients seeking to avoid COVID-19 infection in healthcare settings. Leading players are pursuing strategies such as partnerships and new product developments, exemplified by Voluntis partnering with Biocon biologics in July 2020 to develop digital therapeutics for diabetes patients.